JP2005529587A5 - - Google Patents

Download PDF

Info

Publication number
JP2005529587A5
JP2005529587A5 JP2003576000A JP2003576000A JP2005529587A5 JP 2005529587 A5 JP2005529587 A5 JP 2005529587A5 JP 2003576000 A JP2003576000 A JP 2003576000A JP 2003576000 A JP2003576000 A JP 2003576000A JP 2005529587 A5 JP2005529587 A5 JP 2005529587A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
seq
binding
composition
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003576000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005529587A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/007647 external-priority patent/WO2003077947A1/en
Publication of JP2005529587A publication Critical patent/JP2005529587A/ja
Publication of JP2005529587A5 publication Critical patent/JP2005529587A5/ja
Pending legal-status Critical Current

Links

JP2003576000A 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法 Pending JP2005529587A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36451302P 2002-03-15 2002-03-15
PCT/US2003/007647 WO2003077947A1 (en) 2002-03-15 2003-03-13 Methods of modulating cd200 receptors

Related Child Applications (3)

Application Number Title Priority Date Filing Date
JP2006058745A Division JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134634A Division JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134635A Division JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Publications (2)

Publication Number Publication Date
JP2005529587A JP2005529587A (ja) 2005-10-06
JP2005529587A5 true JP2005529587A5 (enExample) 2006-04-20

Family

ID=28041929

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003576000A Pending JP2005529587A (ja) 2002-03-15 2003-03-13 Ｃｄ２００レセプターを調節する方法
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2006058745A Pending JP2006206598A (ja) 2002-03-15 2006-03-03 Ｃｄ２００レセプターを調節する方法
JP2011134635A Withdrawn JP2011178813A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法
JP2011134634A Withdrawn JP2011178812A (ja) 2002-03-15 2011-06-16 Ｃｄ２００レセプターを調節する方法

Country Status (16)

Country Link
US (3) US20030223991A1 (enExample)
EP (3) EP2100617A1 (enExample)
JP (4) JP2005529587A (enExample)
AT (1) ATE439861T1 (enExample)
AU (3) AU2003220219A1 (enExample)
CA (1) CA2478803A1 (enExample)
CY (1) CY1109521T1 (enExample)
DE (1) DE60328870D1 (enExample)
DK (1) DK1482973T3 (enExample)
ES (1) ES2330211T3 (enExample)
MX (1) MXPA04008937A (enExample)
NZ (2) NZ570998A (enExample)
PT (1) PT1482973E (enExample)
SI (1) SI1482973T1 (enExample)
WO (1) WO2003077947A1 (enExample)
ZA (2) ZA200407384B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002543838A (ja) * 1999-05-13 2002-12-24 メディカル リサーチ カウンシル Ｏｘ２レセプターホモログ
AU2002334997A1 (en) * 2001-10-12 2003-04-22 Schering Corporation Use of bispecific antibodies to regulate immune responses
SI1482973T1 (sl) * 2002-03-15 2010-01-29 Schering Corp Postopki za moduliranje receptorjev CD200
CA2487428A1 (en) * 2002-06-07 2003-12-18 Trillium Therapeutics Inc. Cd200-receptor mediated modulation of bone development
WO2004060295A2 (en) * 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
US20050169870A1 (en) * 2004-02-02 2005-08-04 Schering Corporation Methods of modulating CD200
JP4919453B2 (ja) * 2005-04-07 2012-04-18 独立行政法人理化学研究所 炎症性疾患の予防又は治療剤
DK2037967T3 (en) 2006-06-16 2017-03-13 Univ Pennsylvania PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI
CA2673282A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Antibodies to cd200r
CA2674578A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Compositions and methods relating to manipulation of the myeloid immune compartment during respiratory infection
EP2432499A2 (en) 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP2432805A1 (en) * 2009-05-20 2012-03-28 Schering Corporation Modulation of pilr receptors to treat sepsis
WO2011084357A1 (en) 2009-12-17 2011-07-14 Schering Corporation Modulation of pilr to treat immune disorders
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
TWI677507B (zh) * 2012-06-22 2019-11-21 達特茅斯學院基金會 新穎之ｖｉｓｔａ－ｉｇ構築體及ｖｉｓｔａ－ｉｇ用於治療自體免疫、過敏及發炎病症之用途
EP2892558B1 (en) 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
JP5854432B2 (ja) * 2012-09-28 2016-02-09 森永乳業株式会社 アレルギー反応検出法
CN119775416A (zh) 2013-12-24 2025-04-08 杨森制药公司 抗vista抗体及片段
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
EP3448412A4 (en) 2016-04-15 2020-03-25 Immunext Inc. ANTI-HUMAN-VISTA ANTIBODIES AND USE THEREOF
TWI749367B (zh) * 2018-09-14 2021-12-11 美商美國禮來大藥廠 Cd200r促效劑抗體及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5202267A (en) 1988-04-04 1993-04-13 Hygeia Sciences, Inc. Sol capture immunoassay kit and procedure
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
EP0469477B1 (en) * 1990-08-02 1995-09-20 F. Hoffmann-La Roche Ag Antiallergic combination
US5440021A (en) 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
WO1997045451A1 (fr) 1996-05-27 1997-12-04 Medical & Biological Laboratories Co., Ltd. Anticorps anti-lect2 humains, cellules le produisant et ses procede et materiel de dosage
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
JPH10212242A (ja) * 1996-11-27 1998-08-11 Tosoh Corp 新規血小板増多剤
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US5948627A (en) 1997-05-30 1999-09-07 One Lambda Immunobead flow cytometric detection of anti-HLA panel-reactive antibody
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6989435B2 (en) * 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
JPH11246435A (ja) * 1997-10-29 1999-09-14 Ajinomoto Co Inc 免疫調整剤
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
AU5134799A (en) * 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
JP2002543838A (ja) * 1999-05-13 2002-12-24 メディカル リサーチ カウンシル Ｏｘ２レセプターホモログ
AU2001278338A1 (en) * 2000-08-03 2002-02-18 David A Clark Methods and compositions for modulating tumor growth
US7186818B2 (en) * 2001-04-26 2007-03-06 Immunex Corporation DNA encoding soluble variants of human OX2 receptors
WO2002095030A2 (en) * 2001-05-24 2002-11-28 Trillium Therapeutics Inc. Modulation of cd200 receptors
AU2002334997A1 (en) * 2001-10-12 2003-04-22 Schering Corporation Use of bispecific antibodies to regulate immune responses
US20040126777A1 (en) * 2002-01-28 2004-07-01 Bhatt Ramesh Rajani Lp mammalian proteins; related reagents
SI1482973T1 (sl) * 2002-03-15 2010-01-29 Schering Corp Postopki za moduliranje receptorjev CD200

Similar Documents

Publication Publication Date Title
JP2005529587A5 (enExample)
JP4964957B2 (ja) 抗薬物抗体アッセイ
RU2014104113A (ru) Elisa для vegf
JP2017524725A5 (enExample)
JP2023017841A5 (enExample)
RU2015155552A (ru) Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
RU2004136285A (ru) Способ диагностики гепатоцеллюлярной карциномы
JP2007527406A5 (enExample)
JP2016505634A5 (enExample)
JP2006502416A5 (enExample)
JP2008538919A5 (enExample)
RU2010117018A (ru) Антитела к gdf8 и их применения
JP2002529705A5 (enExample)
JP2007525427A5 (enExample)
JP2018535404A5 (enExample)
KR101806681B1 (ko) 스틸씨병 진단용 바이오마커 조성물, 진단 키트 및 진단 방법
JP2010536043A5 (enExample)
JP2008545145A5 (enExample)
RU2014128510A (ru) Способ определения свободного связывающего партнера мультиспецифичного связующего
DK1125130T3 (da) Påvisning af syreresistente mikroorganismer i afföringen
RU2013109173A (ru) АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
RU2017114626A (ru) Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике
JP2009536818A5 (enExample)
Stevenson et al. Analysis of soluble HLA class II antigenic material in patients with immunological diseases using monoclonal antibodies
JP4413179B2 (ja) 免疫学的粒子凝集反応方法